Antev Overview
- Year Founded
-
2013
- Status
-
Acquired/Merged
- Employees
-
5
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$5.41M
Antev General Information
Description
Operator of the biopharmaceutical firm intended to overcome the historical problems of GnRH (gonadotropin-releasing hormone) in antagonist candidates. The company specializes in the development of therapies in areas including prostate cancer, benign prostatic hyperplasia, and acute urinary retention, along with women's health indications such as endometriosis and uterine fibroids, enabling clients from the healthcare industry to focus on the unmet clinical need for health and develop drugs easily.
Contact Information
Website
www.antev.co.uk(Operating Subsidiary)
Corporate Office
- 106 New Bond Street
- 3rd Floor
- London W1S 1DN
- England, United Kingdom
Corporate Office
- 106 New Bond Street
- 3rd Floor
- London W1S 1DN
- England, United Kingdom
Antev Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Merger/Acquisition | 29-Aug-2025 | $5.41M | Completed | Clinical Trials - Phase 2 | ||
| 3. Later Stage VC | 10-Apr-2024 | Completed | Clinical Trials - Phase 2 | |||
| 2. Seed Round | 13-Apr-2019 | $1.86M | $2.93M | Completed | Clinical Trials - Phase 1 | |
| 1. Seed Round | 21-Sep-2017 | $1.07M | $1.07M | Completed | Clinical Trials - Phase 1 |
Antev Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | 189,484 | $0.012669 | $5.45 | $5.45 | 1x | $5.45 | 6.41% |
Antev Patents
Antev Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025229186-A1 | Composition for use in reducing the risk of recurrent acute urinary retention | Pending | 03-May-2024 | ||
| EP-4643869-A1 | Use of gnrh antagonists such as teverelix to treat acute urinary retention | Pending | 03-May-2024 | ||
| EP-4541365-A1 | Teverelix-tfa in a dosage regime for use in the treatment of prostate cancer | Inactive | 18-Oct-2023 | ||
| EP-4794710-A1 | Teverelix-tfa in a dosage regime for use in the treatment of prostate cancer | Pending | 18-Oct-2023 | ||
| WO-2025083070-A1 | Teverelix-tfa in a dosage regime for use in the treatment of prostate cancer | Inactive | 18-Oct-2023 | A61K38/09 |
Antev Signals
Antev Former Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| S&W (London) | PE-Backed Company | Minority |
Antev Investments (1)
Antev’s most recent deal was a Corporate Asset Purchase with LifeArc (Intellectual Property Rights for Teverelix). The deal was made on 01-Jan-2014.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| LifeArc (Intellectual Property Rights for Teverelix) | 01-Jan-2014 | Corporate Asset Purchase | Buildings and Property |
Antev FAQs
-
When was Antev founded?
Antev was founded in 2013.
-
Where is Antev headquartered?
Antev is headquartered in London, United Kingdom.
-
What is the size of Antev?
Antev has 5 total employees.
-
What industry is Antev in?
Antev’s primary industry is Drug Discovery.
-
Is Antev a private or public company?
Antev is a Private company.
-
What is the current valuation of Antev?
The current valuation of Antev is .
-
What is Antev’s current revenue?
The current revenue for Antev is .
-
How much funding has Antev raised over time?
Antev has raised $14M.
-
Who are Antev’s investors?
S&W (London) has invested in Antev.
-
When was Antev acquired?
Antev was acquired on 29-Aug-2025.
-
Who acquired Antev?
Antev was acquired by Medicus Pharma.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process